252 related articles for article (PubMed ID: 19232037)
1. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
[TBL] [Abstract][Full Text] [Related]
2. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
3. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Metz DC; Vakily M; Dixit T; Mulford D
Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
[TBL] [Abstract][Full Text] [Related]
6. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
Lee RD; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2010 May; 31(9):1001-11. PubMed ID: 20180789
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
Kukulka M; Wu J; Perez MC
J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
[TBL] [Abstract][Full Text] [Related]
9. Dexlansoprazole for the treatment of esophagitis and GERD.
Davies SL
Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
[TBL] [Abstract][Full Text] [Related]
10. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
Croxtall JD; Scott LJ
Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
[TBL] [Abstract][Full Text] [Related]
11. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Wu L; Liu J; Zheng Y; Zhai Y; Lin M; Wu G; Lv D; Shentu J
Clin Drug Investig; 2019 Oct; 39(10):953-965. PubMed ID: 31338800
[TBL] [Abstract][Full Text] [Related]
13. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
Grady H; Murakawa Y; Mulford D; Kukulka M
J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
[TBL] [Abstract][Full Text] [Related]
14. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
Behm BW; Peura DA
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
[TBL] [Abstract][Full Text] [Related]
15. Dexlansoprazole MR: a review.
Hershcovici T; Jha LK; Fass R
Ann Med; 2011 Aug; 43(5):366-74. PubMed ID: 21366513
[TBL] [Abstract][Full Text] [Related]
16. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
Vakily M; Wu J; Atkinson SN
J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
Li YQ; Yan ZY; Zhang HW; Sun LN; Jiao HW; Wang MF; Yu LY; Yu L; Yuan ZQ; Meng L; Wang YQ
Eur J Clin Pharmacol; 2017 May; 73(5):547-554. PubMed ID: 28138748
[TBL] [Abstract][Full Text] [Related]
18. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
19. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
[TBL] [Abstract][Full Text] [Related]
20. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
Zhang W; Wu J; Atkinson SN
J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
